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Summary: This test-negative design case-control study found that over six seasons, 
influenza vaccination protected people with asthma against laboratory-confirmed influenza. 
Protection was highest amongst younger adults (aged 18-54 years). For older adults (>65 
years) protection was only provided against influenza B. 
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Abstract  
Background  
Influenza infection is an important trigger of asthma attacks. Influenza vaccination has the 
potential to reduce the incidence of influenza in people with asthma, but uptake remains 
persistently low, partially reflecting concerns about vaccine effectiveness (VE).   
Methods 
We conducted a test-negative design case-control study to estimate the effectiveness of 
influenza vaccine in children and adults with asthma in Scotland over six influenza seasons 
(2010/11 to 2015/16). We used individual patient level data from 223 primary care practices 
which yielded 1,830,772 patient-years of data, which were linked with hospital and 
virological (n=5,910 swabs) data.   
Results 
Vaccination was associated with an overall 55.0% (95% confidence interval (CI): 45.8-62.7) 
reduction in the risk of a laboratory-confirmed influenza infection in people with asthma over 
the six seasons. There was substantial variation in VE between seasons, influenza strains and 
age groups. The highest VE (76.1%; 95% CI: 55.6-87.1) was found in 2010/11 season where 
the A(H1N1) strain dominated and there was a good antigenic vaccine match. High 
protection was observed against A(H1N1) (e.g. 2010/11: 70.7%; 95%CI: 32.5-87.3) and B 
strains (e.g. 2010/11: 83.2%; 95%CI: 44.3-94.9), but there was lower protection for the 
A(H3N2) strain (e.g. 2014/15: 26.4%; 95%CI: -12.0-51.6). The highest VE against all viral 
strains was observed in adults aged 18-54 years (57.0%; 95%CI: 42.3-68.0).  
Conclusion 
Influenza vaccination gave meaningful protection against laboratory-confirmed influenza in 
people asthma across all six seasons. Strategies to boost influenza vaccine uptake has the 
potential to substantially reduce influenza triggered asthma attacks.  
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INTRODUCTION  
Seasonal influenza results in substantial global morbidity and mortality each year [1, 2]. In 
people with asthma, influenza infection can exacerbate asthma symptoms, which may result 
in asthma attacks necessitating medical attention and in many cases hospital admission [3]. 
The World Health Organization (WHO) and national immunisation programmes recommend 
annual influenza vaccination in people with asthma as the main prophylactic measure against 
influenza [4-6]. In the UK, however, vaccination rates in asthma remain well below the 75% 
uptake target set by the WHO [7]. This suboptimal vaccine uptake is at least in part due to 
uncertainty amongst people with asthma and healthcare providers around the effectiveness of 
influenza vaccines [8]. In the UK, suboptimal vaccine protection is partly addressed with the 
introduction of new vaccine formulations. Specifically, in season 2018/19 younger adults 
aged 18-64 belonging to an at-risk group were offered a quadrivalent inactivated vaccine 
(QIV) and people over 65 years old were offered adjuvanted trivalent inactivated vaccine 
(TIV) [9]
.
The QIV aims to provide better protection by including two influenza B subtypes 
given that influenza B affects younger age groups. The adjuvanted TIV aims to enhance the 
immune response in older people and improve the current suboptimal vaccine effectiveness 
(VE) observed from traditional TIVs [9].  
Our recent systematic review suggested that the vaccine is effective against influenza 
infection in asthma [8]. However, the conclusions of this review were based mainly on 
studies in which the overall quality was rated as low due to methodological issues related to 
the study design and conduct [8]. Two case-control studies published after the search date of 
the literature review assessed VE in individuals with asthma [10]. The first study compared 
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the VE between asthma and non-asthma hospitalised patients for laboratory-confirmed 
influenza [10]. However, there were too few patients with asthma and thus, the study was 
under-powered to determine the effectiveness of the influenza vaccine [10]. In the second 
study, the VE was assessed in children 6-59 months during four seasons by various 
characteristics including asthma [11]. VE of 43.3% was found in the asthma subgroup. 
However, no further analyses in relation to other demographics or other characteristics 
related to influenza infection or the vaccination were performed for the asthma subgroup 
[11].  
Most national immunisation committees assess the VE based on evidence from observational 
studies rather than placebo randomised controlled trials, which are no longer conducted in 
asthma since the vaccination is now a public health recommendation for all at-risk groups 
such as people with asthma [12].
 
Thus, we
 
employed a test-negative design (TND) case-
control study to best determine the VE for each influenza season since it is now seen as the 
gold standard for generating unbiased VE estimates [13-16]. In addition, the large sample 
size of our TND study using swab samples for multiple seasons enabled us to assess various 
factors that affect VE in observational studies such as asthma population characteristics and 
influenza circulating types and subtypes which were not assessed in previous studies due to 
sample size limitations [8]. 
The aim of this study was to assess VE in children and adults with asthma. More specifically, 
the objectives of this study were to: (1) evaluate seasonal influenza VE across and in single 
seasons; (2) evaluate the VE against common seasonal circulating viral strains; and (3) 
provide VE estimates by age groups. 
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METHODS 
Study Design  
We undertook a retrospective observational TND case-control study to evaluate influenza VE 
on patients that seek care for acute respiratory infection. In a TND study, cases are those 
testing positive for influenza and controls are those testing negative for influenza. This study 
included children (>6 months old) and adults who were recommended by UK immunisation 
guidelines to receive influenza vaccination i.e. those treated for asthma requiring continuous 
or repeated use of inhaled or systemic corticosteroids and/or with previous exacerbations 
requiring hospital admission. The study participants were identified from 223 general 
practices (sentinel and non-sentinel) and hospitals for acute respiratory illness from influenza 
season 2010/11 to 2015/16 in Scotland. Patients were swabbed and tested for influenza using 
the multiplex real-time polymerase chain reaction (RT-PCR) assay [17]. Patients with a 
positive test for influenza were classified as cases, while those with a negative test were 
classified as controls. In patients with more than one positive test for influenza, only the first 
positive test was counted as a single case. VE was estimated by comparing positivity 
proportions between the vaccinated and unvaccinated patients [16]. 
The VE assessment in the asthma population was an objective of the Seasonal Influenza 
Vaccine Effectiveness (SIVE) II project [18] (see included datasets in Figure 1). See 
Supplementary Appendix 1 for details.   
Exposure and Outcome Assessment  
The exposure status was based on vaccination administrated between the pre-influenza 
season and the end of the influenza season. Individuals vaccinated from 1 September until the 
end of the influenza season defined the “exposed” group. Individuals with no vaccination 
record, being vaccinated after being tested for influenza, or vaccinated within 14 days prior to 
testing were also classified as the “unexposed” group [18].  
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General practices who were part of the sentinel scheme obtained nasal or nasopharyngeal 
swabs from patients with influenza-like illness (ILI) symptoms. General Practitioners usually 
collected swab samples from patients presenting with ILI symptoms (independent of whether 
the patient has or has not been vaccinated) within seven days of date of onset of those 
symptoms. Each general practice collected up to five samples per week and submitted these 
to the West of Scotland Specialist Virology Centre (WoSSVC) [18]. Each swab sample 
collected in general practice sentinel settings was tested by the WoSSVC using the multiplex 
RT-PCR test for a range of  respiratory pathogens, including influenza [18]. For non-sentinel 
practices or secondary care, other laboratories were involved in testing. Subtype and genetic 
characterisation was performed for positive influenza sentinel samples and most of non-
sentinel general practice and hospital samples. Data on laboratory tests carried out in non-
sentinel primary and secondary health care facilities were also collected by the ECOSS 
database. See Supplementary Appendix 2 for baseline characteristics description.  
Statistical Analysis  
Baseline characteristics of study participants were described. The relation between 
vaccination status and baseline characteristics was also provided for cases and controls. 
Proportions and odds ratios (ORs) were used to describe differences between study groups 
depending on the nature of each variable. All baseline population characteristics were 
presented as categorical variables and the x
2
 test was used to describe any association in 
relation to exposure or outcome. Any missing data were reported. All tests were two-tailed 
and results considered significant if P<0.05. See Supplementary Appendix 3 and 4 for details 
on unit of analysis and meta-analysis.  
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Primary and Secondary Analysis  
Pre-specified subgroup analyses as per our published protocol
 
included the provision of VE 
for influenza A and B strains per season [18]. Post-hoc analysis not specified in our protocol 
were also carried out in this study. Specifically, we stratified the VE by age groups in order to 
investigate the age where immunosenescence begins in adults.  
Vaccine Effectiveness 
VE and their 95% CIs were estimated using the formula VE = (1- aOR) x 100 based on 
adjusted OR (aOR) [18]. ORs were calculated by the regression coefficients of vaccine status 
in the model. A generalised additive logistic regression model was used to explain the 
relationship between influenza infection and influenza vaccine in presence of other 
confounding covariates. The model provided VE estimates adjusted for the effects of the 
covariates: time, age, underlying medical conditions and the source of swab sample collection 
which were either statistically or epidemiologically associated with the outcome. Adjustment 
for time was performed for all VE estimates. Time was measured in days from the beginning 
of October each season. It was included as a spline function to account for bias related to time 
differences between influenza circulation and vaccine administration during each season [18]. 
Sample Size  
Using data from a previous study [18] we anticipated 1454 asthma patients would be 
swabbed over the two seasons 2014-2016.  We assumed that 582 or 40.0% (1,454*0.40) of 
asthma patients had been vaccinated for influenza and the number of tests positive for 
influenza was 218 or 15.0% (1,454*0.15), which gave an 80.0% power to detect a VE of 
33.0% [18].  The study recruited 1413 patients swabbed in 2014/15 and 1670 in 2015/16. 
Sample size details are provided in Supplementary Appendix 5 and statistical analyses were 
carried out using R Version 3.4.2 and RStudio (Version 1.0.143) [19]
 
within the NHS 
Scotland data safe haven. 
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Ethical Considerations 
The Privacy Advisory Committee of the Information Services Division, NSS, approved the 
linkage and the statistical analysis of the anonymised data used in this study.  
Reporting 
We used the Strengthening the Reporting of Observational studies in Epidemiology 
(STROBE) and REporting of studies Conducted using Observational Routinely-collected 
Data (RECORD) checklists to guide transparent reporting of this TND case-control study 
(See Supplementary Appendix 6 and 7) [20-21]. 
RESULTS 
A total registered primary care asthma population of 1,830,772 person-years out of 194,319 
people with asthma was recruited in this study over a 16-year period. These data were 
collected as part of the SIVE II study [18] and included a total of 5,910 swab samples taken 
from 5,022 asthma patients from 2010/11 to 2015/16 (Figure 2). These swabs were carried 
out in primary or secondary care settings from people with asthma and tested for influenza 
with the RT-PCR test. There were 781 of 5,910 (13.2%) swabs tested positive for influenza 
and were classified as cases (Table 1) and (86.8%) tested negative for influenza and were 
classified as controls (Figure 2). Patients more likely to test positive for influenza were aged 
45-64 years (15.1%), lived in remote small towns (>10%), with no previous seasonal 
influenza vaccine (15.2%) and had a swab sample collected from a primary care setting 
(16.7%) (Table 2).  
Vaccine effectiveness by season and influenza type and subtype  
The VE for the commonly influenza circulating strains was estimated for each strain in each 
influenza season.  
In 2010/11, the overall VE was high (76.1% [95%CI: 55.6-87.1]) with A/H1N1 and B 
predominating (Table 3). In 2011/12, the overall VE was lower and imprecise (45.1% 
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[95%CI: -35.1.1-77.7]) with A/H3N2 predominating. Slightly higher and more precise 
overall VE of 45.2% (95%CI: 13.8-65.1) was observed in the 2012/13 season where all 
influenza A subtypes co-dominated. The overall VE in 2013/14 (where the predominant 
strain was A/H1N1) was 52.3% (95%CI: 6.5-75.6). In 2014/15, an overall VE of 48.6% (95% 
CI: 27.8-63.4) was found with a high swab positivity (16.4%) and predominant strains H3N2 
and B. In 2015/16 season, the overall VE of 57.8% (95%CI: 40.1-70.3) was higher compared 
to previous seasons (apart from 2010/11), the predominant strains were A/H1N1 and B and 
the swab positivity was 12.0%.  
 
In 2010/11, we found high VE for the influenza A(H1N1) subtype and B with estimates of 
70.7% (95% CI: 32.5-87.3) and 83.2% (95% CI: 44.3-94.9) respectively (Table 3). In 
2011/12 season a small number of cases of influenza A(H3) subtype and B resulted in low 
and imprecise VE estimates of 3.7% (95%CI: -240.5-75.0) and 71.8% (95%CI: -358.1-98.3) 
respectively. In the 2012/13 season where all influenza A subtypes co-dominated, a 
particularly high VE of 77.5% (95% CI: 9.8-94.4) was observed for A(H1N1), but lower VE 
was found for the co-circulating influenza A(H3) and B strains. In 2013/14 a VE of 32.0% 
(95%CI: -52.2-69.6) was observed for the influenza A(H1N1) subtype - imprecision in the 
VE estimate was due to low swab positivity. In 2014/15, a high VE of 77.0% (95% CI: 53.9-
88.5) for influenza B was found. In 2015/16 the swab positivity was 12.0% and a VE 
estimate of 54.7% (95% CI: 19.5-74.5) was observed for influenza B. 
Pooled vaccine effectiveness by influenza type and subtype   
The overall VE estimate was 54.9% (95% CI: 44.4-63.4) against influenza A and B types as 
it is shown by the OR provided in the random effect model (Figure 3). Heterogeneity for this 
pooled estimate was detected but it was small. A substantially low VE estimate of 29.3% 
(95% CI: 1.0-49.4) was detected for influenza A(H3), but no heterogeneity was found (Figure 
4). A higher pooled VE of 48.4% (95% CI: 19.4-66.9) was found against influenza A(H1N1) 
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compared to influenza A(H3). Low-to-moderate heterogeneity was observed across seasons 
(Figure 5). The highest pooled VE of 60.8% (95% CI: 31.6-77.5) was detected for influenza 
B. Higher heterogeneity was also observed for the influenza B compared to other strains but 
it was non-significant. Unadjusted OR was used for the 2013/14 season due to zero adjusted 
OR. This happened due to low circulating levels of influenza B strains resulting in small to 
zero OR which would have prohibited the provision of any meaningful OR in the meta-
analysis and a subsequent VE estimation (Figure 6).  
 
Vaccine effectiveness by age group  
This analysis showed that the VE was low in those 55 years and above against influenza A 
subtypes (except 65-74 years old for A(H1N1)) while high VEs for influenza B were found. 
VE was high in children (<18 years old) with a VE of 90.5% against A(H1N1) (Table 4).  
 
DISCUSSION  
During six influenza seasons influenza vaccination effectiveness was over 50% for 
laboratory-confirmed influenza in people with asthma. Better protection was observed during 
seasons with good antigenic match and against the A(H1N1) and B strains. Moderate VE was 
found against influenza A(H1N1) (47%) and influenza B (62%) and VE was low for 
influenza A(H3N2) (34%). The seasonal influenza vaccine provided protection in younger 
adults (aged 18-54 years old) against influenza A(H1N1), influenza A(H3) subtypes and 
influenza B.  
The highest VE was observed in 2010/11 which was characterised by high influenza activity 
predominated by the influenza A(H1N1) and B strains in the UK [22-23].
 
While low VE was 
detected in 2011/12, this is likely due to low and late activity of the predominant A(H3) strain 
and an antigenic vaccine mismatch [24]. Intra-seasonal VE waning and low VE against the 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1086/5613421 by guest on 14 N
ovem
ber 2019
 12 
 
A(H3N2) was observed in the UK and US [8, 25-26].
 
This lower VE has been attributed to 
antigenic drift [26]. In the 2012/13 season, good protection was only found against the 
A(H1N1) strain; this was consistent with the findings from another UK study [27]. Antigenic 
drift  for influenza B and VE decline for influenza A(H3N2) particularly in the second 
trimester following vaccination was noted during this season [27-28]. A US study including 
1,259 people with asthma  reported a moderate VE of 46% in 2012/13 [8, 29]. 
We found overall protection against influenza in 2013/14 where the influenza activity was 
low and prolonged, influenza A(H1N1) dominated and the vaccine was well matched [30]. In 
2014/15, there was vaccine stain mismatch for H3N2, we observed a positive VE for 
influenza B similar to findings in  a UK-wide study [31]. In the 2015/16 season, our finding 
of  an overall positive VE is consistent with the VE of 55% found in a UK study [32]. The 
influenza A(H1N1) strain predominated and the vaccine was well matched for this sub-
type[33]. We also observed a high VE against influenza B despite lineage mismatch with the 
vaccine – also found in another study[32].  
The overall VE of 46% in children in this study was similar to a recent TND study in Canada 
where the VE was 43% in children [11]. However, in our study, protection was found only 
against the B strain while previous studies have shown also protection against A(H1N1) [34-
35]. Lower strain-specific protection was observed in older adults (aged >55 years old) and 
no protection was found against influenza A strains. Nevertheless, the VE decrease in >55 
years old may only be indicative of immunosenescence and further better powered studies are 
needed to investigate this phenomenon. There is evidence that the VE in those over the age of 
75 may be lower than in those age 65-74 years [36]. The mechanism for this is uncertain, but 
may be explained by reduced immune responsiveness to historically used influenza antigens 
in the most elderly [36]. Such evidence has led to the development and introduction of either 
adjuvanted influenza vaccines or high dose influenza vaccines in this age group. In addition, 
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the effects of other factors such as the presence of other underlying conditions in older 
persons could explain the decrease in VE estimates in this age group.  
The strengths of this study include the influenza diagnosis based on a test with high 
predictive value and reduction of any recall or misclassification bias due to documentation of 
vaccination and medical condition status in high quality electronic medical records [37]. 
Additionally, the TND study minimised the effects of selection bias due to differential 
healthcare seeking behaviour between cases and controls by assessing only the prevention of 
the vaccine against medically-attended influenza. The inclusion of six seasons increased the 
power of the study allowing the provision of VE estimates for different seasons, strains and 
patient characteristics. Thus, this study’s findings can be generalised to the wider asthma 
population in Scotland.  
Several limitations also need to be considered in this study. The VE in this study assessed 
only the prevention of influenza. However, vaccinated individuals may have also been 
benefited by having less severe influenza illness and a subsequent lower risk of a severe 
asthma attack. Thus, vaccine protection provided by decrease in influenza severity cannot be 
quantified in this study [14, 16, 38]. Although the general practice electronic health record 
includes vaccinations taking place in non-general practice settings, there may be some 
misclassification of vaccination status. Results from the post-hoc analyses need careful 
interpretation since they were not pre-specified in the protocol of this study. Unmeasured 
confounders could still have influenced the VE estimates. Future research should assess the 
confounding effect on VE from TND studies. TND studies offer an elegant way to deal with 
selection bias related to healthcare-seeking behaviour between cases and control. However, 
bias may occur due to differences in healthcare seeking behaviour between vaccinated and 
unvaccinated patients and swab testing may also differ between vaccinated and non-
vaccinated patients particularly in non-sentinel settings [39].  
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This study showed that vaccination can prevent influenza in individuals with asthma 
presented with ILI in Scottish primary and secondary care settings. While substantial 
variation in VE was observed among circulating strains and age groups, protection was still 
observed in most subgroups. There was significant pooled VE when the A(H1N1) dominated 
that could be explained by the absence of vaccine mismatch over the three seasons [23, 30, 
33]. While the lower pooled VE when the A(H3) dominated could be due to vaccine 
mismatch in most seasons and the intra-seasonal VE waning [27, 30]. Generally, the 
protection against the A(H3N2) is usually lower compared to A(H1N1) and B which is 
around 60% or even higher [40]. Thus, evidence from this study reinforces the 
recommendation for annual seasonal vaccination in asthma. Although, there are current 
developments towards universal vaccines with better potency, durability and wide protection, 
these vaccines may not be available for another decade [41]. Thus, monitoring of the 
effectiveness of current vaccines should be continued. Further adequately powered studies 
will be needed to monitor the effectiveness of these vaccines in groups of the population at 
risk of severe influenza and complications such as persons with asthma.  
The findings of this study can guide research and policymakers for the provision of a more 
targeted and effective vaccination programme improving the current protection of the asthma 
population. Specifically, policy makers and clinicians should consider adjuvant vaccine or 
high dose influenza vaccine in people with asthma aged 55 years and above [9]. Healthcare 
providers and people with asthma will also have now a clearer answer regarding the value of 
the influenza vaccination which is prevention of influenza infection in children and adults 
with current asthma. 
In summary, we provide compelling national evidence over a number of years that influenza 
vaccination substantially reduces the risk of influenza in people with asthma. There is a need 
for strategies to boost influenza vaccination uptake in people with asthma.  
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FIGURE LEGENDS 
Figure 1: Phases of data extraction, linkage and analysis in a secured environment.  
 
Figure 2: Flow diagram for the test-negative design case-control study for an asthma 
population for the influenza seasons 2010/11 to 2015/16, Scotland, UK.  
 
Figure 3: Vaccine effectiveness against laboratory confirmed overall influenza (Influenza A 
and B) by season. 
*Season with poorly matched vaccine  
^Season with high influenza attack rate  
 
Figure 4: Vaccine effectiveness against laboratory confirmed influenza A(H3) subtype by 
season.  
  *Season with poorly matched vaccine 
  ^Season with high influenza attack rate  
 
Figure 5: Vaccine effectiveness against laboratory confirmed influenza A(H1N1) subtype by 
season.  
  *Season with poorly matched vaccine 
  ^Season with high influenza attack rate 
 
Figure 6: Vaccine effectiveness against laboratory confirmed influenza B subtype by season  
*Season with poorly matched vaccine. 
^Season with high influenza attack rate 
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Table 1: Number of influenza (sub)types out of the 781 influenza positive cases 
Influenza  (sub)types No. of influenza (sub)types / No. of cases (%) 
Influenza A 581/781  (74.4) 
A(H1N1) 240/781  (30.7) 
A(H3) 208/781  (26.6) 
A(unknown) 133/781  (17.0) 
Influenza B 205/781  (26.2) 
Influenza A & B     5/781    (0.6) 
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Table 2: Baseline characteristics for cases and controls with asthma during six seasons, Scotland, 2010-16 (n=5,910) 
Covariates 
Total samples 
(% of total) 
No. Vaccinated  
at test 
(% of total) 
P value* No. of positive 
swabs 
(% of total) 
P value Swab-positive 
adjusted OR
a
 
Adjusted  
95% CI 
Gender                                                                                                   
  Female (reference) 3,575 (60.5) 1,777 (49.7) 0.04 469 (13.1) 0.79 NA NA 
  Male  2,335 (39.5) 1,097 (47.0) 312 (13.4) 1.02 0.88 to 1.19 
Age group (years)
 b
 
  0-1  5 (0.1) 3  (60.0) <0.001 0 (0.0) 0.0004 8.688845e-06 1.320726e-209 to 
5.716258e+198 
  2-4 169 (2.9)  64 (37.9) 11 (6.5) 0.47 0.25 to 0.90 
  5-11 530 (9.0) 213 (40.2) 45 (8.5) 0.63 0.44 to 0.91 
  12-17 371 (6.3) 119 (32.1)   45 (12.1) 0.94 0.65 to 1.35 
  18-44  1615 (27.3) 436 (27.0) 234 (14.5) 1.15 0.90 to 1.47 
  45-64  1625 (27.5) 826 (50.8) 246 (15.1) 1.21 0.95 to 1.54 
  65-74    747 (12.6) 549 (73.5)    91 (12.2) 0.94 0.70 to 1.27 
  >75 (reference)    847 (14.3) 663 (78.3) 109 (12.9) NA NA 
Deprivation quintile
c
 
  1
d
 (reference) 1350 (22.8) 620 (45.9) 0.06 178 (13.2) 0.69 NA NA 
  2 1486 (25.1) 732 (49.3) 184 (12.4) 0.93 0.75 to 1.16 
  3 1035 (17.5)  531 (51.3) 147 (14.2) 1.09 0.86 to 1.38 
  4   976 (16.5)  465 (47.6) 130 (13.3) 1.01 0.79 to 1.29 
  5   938 (15.9)  475 (50.6) 116 (12.4) 0.93 0.72 to 1.19 
Urban/rural score
e
 
  1 (reference) 3210 (54.3) 1573 (49.0) 0.003 352 (11.0) <0.001 NA NA 
  2 1459 (24.7)   676 (46.3) 228 (15.6) 1.50 1.26 to 1.80 
  3 381 (6.4)   183 (48.0)   63 (16.5) 1.61 1.19 to 2.14 
  4   91 (1.5)     40 (44.0)   16 (17.6) 1.73 0.97 to 2.93 
  5   54 (0.9)     22 (40.7)   14 (25.9) 2.84 1.48 to 5.15 
  6 448 (7.6)    253 (56.5)    57 (12.7) 1.18 0.87 to 1.58 
  7   63 (1.1)     24 (38.1)    16 (25.4) 2.76 1.51 to 4.82 
  8
f
      118 (2.0)     65 (55.1)    17 (14.4) 1.37  0.78 to 2.25 
COPD   775 (13.1) 522 (67.4) <0.001 95 (12.3) 0.40 0.91 0.72 to 1.13 
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Chronic heart disease   722 (12.2) 527 (73.0) <0.001 92 (12.7) 0.69 0.95 0.75 to 1.20 
Chronic liver disease 112 (1.9)  56 (50.0) 0.77 15 (13.4) 0.96 1.02 0.56 to 1.70 
Chronic neurological 
disease 
357 (6.0) 251 (70.3) <0.001 45 (12.6) 0.73 0.94 0.68 to 1.29 
Diabetes    597 (10.1) 417 (69.8) <0.001 75 (12.6) 0.62 0.94 0.72 to 1.20 
Immunosupression      166 (2.8)   85 (51.2) 0.5 18 (10.8) 0.36 0.79 0.47 to 1.27 
Number of risk groups (comorbidities)  
  1 (reference) 3693 (62.5) 1440 (39.0) <0.001  490 (13.3) 0.71 NA NA 
  2 1042 (17.6)   632 (60.7) 141 (13.5 1.02 0.83 to 1.25 
  3   705 (11.9)   461 (65.4)    95 (13.5) 1.02 0.80 to 1.28 
  4  333 (5.6)   241 (72.4)    39 (11.7) 0.87 0.60 to 1.21 
  5  112 (1.2)     81 (72.3)  11 (9.8) 0.71 0.36 to 1.28 
  6     25 (0.4)     19 (76.0)     5 (20.0)  1.63 0.54 to 4.06 
Influenza vaccine in previous season 
Yes 3352 (56.7) 2417 (72.1) <0.001 392 (11.7) <0.001 0.74 0.64 to 0.86 
No (reference) 2558 (43.3)   457 (17.9) 389 (15.2) NA NA 
Swab samples taken in general practices or hospitals 
General practice 
(reference)  
873 (14.8) 359 (41.1) <0.001 146 (16.7) 0.0005 NA NA 
Hospital 5010 (84.8) 2494 (49.8)   628 (12.5) 0.71 0.59 to 0.87 
Unknown    27 (0.5)      21 (77.8)       7 (25.9) 1.74 0.67 to 4.02 
Abbreviations: OR: odds ratio; CI: confidence interval; NA: not applicable  
a Adjusted for gender, age and socioeconomic deprivation 
b Age group available for 5,909 swabs  
c Deprivation score only available for 5,785 swabs 
d Most socioeconomically deprived  
e Urban/rural score only available for 5,824 swabs  
f Remote rural areas 
* All p-values were estimated using the x
2 
test  
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Dominant circulating 
strain(s) for each 
influenza season 
Influenza 
types & 
subtypes 
Influenza-positive 
(cases) 
Influenza-negative 
(controls) 
Total 
positive 
(%) 
Unadjusted 
vaccine 
effectiveness
a
 
(95% CI) 
Adjusted 
vaccine 
effectiveness
b
 
(95% CI) 
Vaccinated/ 
total (n) 
Vaccinate
d (%) 
Vaccinated/ 
total (n) 
Vaccinate
d (%) 
Season: 2010-2011 
 
A/California/07/2009 
(H1N1)pdm2009 
 
B/Brisbane/60/2008 
Influenza A & 
B 
29/123 23.6 176/364 48.4 25.3 70.1 
(49.5 to 82.3) 
76.1 
(55.6 to 87.1) 
A(H3) 0/0 0.0 205/487 42.1 0.0 0.0 
(-Inf to 100) 
0.0 
(-Inf to100) 
A(H1N1) 17/79 21.5 188/408 46.1 16.2 68.8 
(37.9 to 84.3) 
70.7 
(32.5 to 87.3) 
Influenza B 5/26 19.2 200/461 43.4 5.3 78.0 
(37.3 to 92.3) 
83.2 
(44.3 to 94.9) 
Season: 2011-2012 
 
A/Victoria/208/2009 
(H3N2) 
Influenza A & 
B 
14/28 50.0 241/546 44.1 4.9 34.4 
(-44.3 to 70.1) 
45.1 
(-35.1 to 77.7) 
A(H3) 6/11 54.6 249/563 44.2 1.9 20.1 
(-173.0 to 76.6) 
3.7 
(-240.5 to 75.0) 
A(H1N1) 0/0 0.0 255/574 44.4 0.0 0.0 
(-Inf to 100) 
0.0 
(-Inf to 100) 
Influenza B 2/5 40.0 253/569 44.5 0.9 57.1 
(-186.7 to 93.6) 
71.8 
(-358.1 to 98.3) 
Season: 2012-2013 
 
A/Victoria/208/2009 
(H3N2) 
A/St Petersburg/27/2011 
(H1N1) 
B/Brisbane/60/2008 
B/Brisbane/3/2007 
B/Massachusetts/02/2012 
Influenza A & 
B 
50/143 35.0 323/691 46.7 17.2 48.2 
(22.2 to 65.5) 
45.2 
(13.8 to 65.1) 
A(H3) 17/45 37.8 356/789 45.1 5.4 27.9 
(-36.3 to 61.9) 
38.0 
(-25.7 to 69.4) 
A(H1N1) 3/17 17.7 370/817 45.3 2.0 79.8 
(28.3 to 94.3) 
77.5 
(9.8 to 94.4) 
Influenza B 18/53 34.0 355/781 45.5 6.4 40.0 
(-9.8 to 67.3) 
11.7 
(-70.7 to 54.3) 
Table 3: Vaccine effectiveness for laboratory-confirmed influenza type and subtype by season, Scotland, 2010-16 
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Season: 2013-2014 
 
A/California/07/2009 
(H1N1)pdm09 
Influenza A & 
B  
26/54 48.2 457/878 52.1 5.8 37.7  
(-10.7 to 64.9) 
52.3 
(6.5 to 75.6) 
A(H3) 2/6 33.3 481/926 51.9 0.6 65.9 
(-105.0 to 94.3) 
-3.9 
(-1304.5 to 
92.3) 
A(H1N1) 18/34 52.9 465/898 51.8 3.7 21.4  
(-59.2 to 61.2) 
32.0  
(-52.2 to 69.6) 
Influenza B 2/5 40.0 481/927 51.9 0.5 45.2 
(-259.1 to 91.7) 
100  
(0 to 100) 
Season: 2014-2015 
 
A/Texas/50/2012 (H3N2) 
B/Yamagata/16/88 
Influenza A & 
B 
122/232 52.6 605/1181 51.2 16.4 36.3 
(13.3 to 53.2) 
48.6 
(27.8 to 63.4) 
A(H3) 
 
79/140 56.4 648/1273 50.9 9.9 21.1 
(-16.0 to 46.4) 
26.4 
(-12.0 to 51.6) 
A(H1N1) 
 
5/6 83.3 722/1407 51.3 0.4 -290.9 
(-3301.3 to 55.1) 
-157.0 
(-2565.5 to 
75.2) 
Influenza B 20/49 40.8 707/1364 51.8 3.5 62.0 
(30.3 to 79.3) 
77.0 
(53.9 to 88.5) 
Season: 2015-16  
 
A/California/07/2009 
(H1N1)pdm09 
B/Brisbane/60/2008 
Influenza A & 
B 
85/201 42.3 746/1469 50.8 12.0 54.8 
(37.8 to 67.1) 
57.8 
(40.1 to 70.3) 
A(H3) 
 
2/6 33.3 829/1664 49.8 0.4 39.0  
(-294.0 to 90.5) 
78.1 
(-102.6 to 97.6) 
A(H1N1) 51/104 49.0 780/1566 49.8 6.2 32.8  
(-2.0 to 55.7) 
36.7 
(-0.6 to 60.2) 
Influenza B 26/67 38.8 805/1603 50.2 4.0 60.9 
(33.9 to 76.8) 
54.7  
(19.5 to 74.5) 
Abbreviations: CI: confidence interval; NA: not applicable  
a  Adjusted for time (i.e. days) only 
b
 
Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. general practice or hospital) 
-There are cases with unknown influenza A subtype which explains why the total influenza A(H3) and A(H1N1) samples do not add exactly to the total  
influenza A samples   
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Age 
(years)  
Influenza types 
& subtypes 
Influenza-positive  
(cases) 
Influenza-negative 
 (controls) 
Total 
positive 
(%) 
Unadjusted vaccine 
effectiveness
a
 
(95% CI) 
Adjusted vaccine 
Effectiveness
b
 
 (95% CI)
 
 
Vaccinated/ 
total (n) 
Vaccinated  
(%) 
Vaccinated/ 
total(n) 
Vaccinated 
(%) 
All ages Influenza A & B 326/781 41.7 2548/5129 49.7 13.2 48.6 
(39.2 to 56.6) 
55.0 
(45.8 to 62.7) 
A(H3) 106/208 51.0 2768/5701 48.5 3.5 26.0 
(-0.8 to 45.6) 
33.8 
(6.7 to 53.1) 
A(H1N1) 94/240 39.2 2780/5670 49.0 4.1 43.2 
(23.6 to 57.8) 
46.6 
(25.4 to 61.8) 
Influenza B 73/205 35.6 2801/5705 49.1 3.5 59.0 
(44.2 to 70.0) 
61.5 
(45.7 to 72.7) 
<17  Influenza A & B 31/101 30.7 368/974 37.8 9.4 52.9 
(23.4 to 71.0) 
46.0 
(11.2 to 67.2) 
A(H3) 8/26 30.8 391/1049 37.3 2.4 55.7  
(-11.0 to 82.3) 
51.1 
(-25.4 to 80.9) 
A(H1N1) 4/15 26.7 395/1060 37.3 1.4 64.9 
(-66.8 to 92.6) 
90.5 
(-45.3 to 99.4) 
Influenza B 12/45 26.7 387/1030 37.6 4.2 69.6 
(26.1 to 87.5) 
56.3 
(3.8 to 80.2) 
18-54  Influenza A & B 94/376 25.0 733/2093 35.0 15.2 54.0 
(39.2 to 65.2) 
57.0 
(42.3 to 68.0) 
A(H3) 22/84 26.2 805/2385 33.8 3.4 58.4 
(28.4 to 75.8) 
53.3 
(17.9 to 73.5) 
A(H1N1) 33/143 23.1 794/2326 34.1 5.8 45.7 
(14.4 to 65.5) 
53.0 
(23.8 to 71.1) 
Influenza B 22/89 24.7 805/2380 33.8 3.6 49.9 
(15.9 to 70.1) 
54.5 
(21.1 to 73.7) 
55-64  Influenza A & B 51/104 49.0 384/667 57.6 13.5 51.1 
(22.0 to 69.4) 
57.6 
(29.6 to 74.5) 
Table 4: Vaccine effectiveness for laboratory-confirmed influenza by various age groups, Scotland, 2010-16 (n=5,910) 
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A(H3) 18/29 62.1 417/742 56.2 3.8 2.6 
(-145.9 to 61.4) 
2.1 
(-178.5 to 65.6) 
A(H1N1) 17/33 51.5 418/738 56.6 4.3 38.0 
(-36.3 to 71.8) 
38.7 
(-43.4 to 73.8) 
Influenza B 7/24 29.2 428/747 57.3 3.1 78.7 
(45.0 to 91.8) 
88.2 
(61.2 to 96.4) 
65-74 Influenza A & B 61/91 67.0 488/656 74.4 12.2 54.8 
(22.5 to 73.6) 
56.8 
(24.0 to 74.9) 
A(H3) 18/24 75.0 531/723 73.4 3.2 -13.4 
(-249.3 to 63.2) 
1.0 
(-196.9 to 67.0) 
A(H1N1) 22/30 73.3 527/717 73.5 4.0 57.5 
(-37.4 to 86.9) 
60.5 
(-37.9 to 88.7) 
Influenza B 12/20 60.0 537/727 73.9 2.7 65.3 
(9.0 to 86.8) 
65.8 
(5.2 to 87.6) 
>75 Influenza A & B 89/109 81.7 575/739 77.8 12.9 48.9 
(4.8 to 72.5) 
51.9 
(9.2 to 74.5) 
A(H3) 40/45 88.9 624/803 77.7 5.3 -13.5 
(-232.9 to 61.3) 
-15.4 
(-278.2 to 64.8) 
A(H1N1) 18/19 94.7 646/829 77.9 2.2 -542.3 
(-6752.7 to 39.8) 
-501.0 
(-5639.5 to 37.1) 
Influenza B 20/27 74.1 644/821 78.4 3.2 67.6 
(15.1 to 87.6) 
70.4 
(19.8 to 89.1) 
Abbreviations: CI: confidence interval 
a  Adjusted for time within a season (i.e. days) 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital)  
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Figure 1 
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Figure 2 
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Figure 3 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz1086/5613421 by guest on 14 N
ovem
ber 2019
 33 
 
Figure 4 
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Figure 5 
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Figure 6 
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